Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Improving the diagnosis of bladder cancer in the BladderPath study

The staging and grading of bladder cancer has not changed in over a century, with endoscopic resection determining if the cancer is muscle invasive or non-muscle invasive. Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, describes the rationale behind the BladderPath study (ISRCTN35296862), which aims to replace the current, invasive techniques with scans and biopsies to diagnose bladder cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.